Skin electroporation of a plasmid encoding hCAP-18/LL-37 host defense peptide promotes wound healing by Steinstraesser, Lars et al.
original article © The American Society of Gene & Cell Therapy
Host defense peptides, in particular LL-37, are emerg-
ing as potential therapeutics for promoting wound 
healing and inhibiting bacterial growth. However, 
effective delivery of the LL-37 peptide remains limiting. 
We hypothesized that skin-targeted electroporation of 
a plasmid encoding hCAP-18/LL-37 would promote the 
healing of wounds. The plasmid was efficiently deliv-
ered to full-thickness skin wounds by electroporation 
and it induced expression of LL-37 in the epithelium. 
It significantly accelerated reepithelialization of non-
diabetic and diabetic wounds and caused a signifi-
cant VEGFa and interleukin (IL)-6 induction. IL-6 was 
involved in LL-37–mediated keratinocyte migration in 
vitro and IL-6 neutralizing antibodies delivered to mice 
were able to suppress the wound healing activity of 
the hCAP-18/LL-37 plasmid. In a hindlimb ischemia 
model, electroporation of the hCAP-18/LL-37 plasmid 
increased blood perfusion, reduced muscular atrophy, 
and upregulated the angiogenic chemokines VEGFa 
and SDF-1a, and their receptors VEGF-R and CXCR-4. 
These findings demonstrate that a localized gene ther-
apy with LL-37 is a promising approach for the treat-
ment of wounds.
Received 8 May 2013; accepted 16 October 2013; advance online  
publication 7 January 2014. doi:10.1038/mt.2013.258
INTRODUCTION
The treatment of difficult to heal wounds is a major clinical prob-
lem worldwide. In particular, chronic nonhealing skin ulcers are 
one of the major complications for diabetic patients. Skin and soft 
tissue infections are the most common indications for antimicro-
bial therapy1 but the emergence of bacterial resistances against 
clinically used antibiotics complicates the treatment and under-
scores the need for new therapeutic options.2,3 Antimicrobial pep-
tides, also called host defense peptides, are effector molecules of 
innate immunity known to play a major role in nonspecific host 
defense against pathogens. They serve as first line of defense and 
display both direct killing of microbes and immunomodulatory 
properties.4 The only antimicrobial peptide of the cathelicidin 
family identified in humans is hCAP-18/LL-37 and is produced 
as a prepropeptide. The extracellular cleavage of hCAP-18 by 
proteinase 3 releases a cathelin-like domain and the 37-amino-
acid-long C-terminus LL-37 bioactive peptide.5 In addition to its 
broad range of antimicrobial activities against bacteria, fungi, and 
viruses, human LL-37 appears particularly interesting for wound 
healing because it also promotes neovascularization.6,7 Moreover, 
it is involved in reepithelialization and granulation tissue forma-
tion for skin wound repair.8 Previous studies with mice deficient 
for the murine cathelicidin CRAMP, an ortholog of human LL-37, 
also uncovered a direct role in the maintenance of a first line of 
defense against bacterial skin infections.9 In accordance with these 
findings, chronic wounds of elderly patients who fail to express 
LL-37 in the epidermis but still express LL-37 in polymorphonu-
clear neutrophils were colonized with S. aureus.10 Recent clinical 
data about the expression of host defense peptides in diabetic foot 
ulcers revealed significant underexpression of LL-37 compared to 
healthy donors,11 raising the hypothesis that a restoration of LL-37 
expression might contribute to the healing of diabetes wounds.
The in vivo delivery of LL-37 is challenging. Indeed, topical 
wound treatment using LL-37 peptide was not able to promote 
healing in diabetic mice,12 suggesting that proteolytic enzymes in 
diabetic wounds might have reduced the peptide half-life. It has 
been recently demonstrated that release of elastase by P.  aeruginosa 
in chronic human ulcers inactivates LL-37 and induces hCAP-18 
propeptide degradation in neutrophils, providing protection of 
bacteria against host defense mechanisms.13 The human catheli-
cidin hCAP-18/LL-37 has previously demonstrated its potential 
to promote diabetic wound healing in vivo after cutaneous ade-
noviral gene delivery.14 Adenoviral delivery of hCAP-18/LL-37 
in P. aeruginosa-infected burn wounds led to high inhibition of 
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bacterial growth, which was 1,000-fold stronger than with treat-
ment by the synthetic LL-37 peptide,15 suggesting a need for the 
sustained presence and continuous production of the peptide 
into the wound site. As viral gene transfer requires particular 
biosafety measures,16 the development of nonviral delivery meth-
ods is appealing for potential clinical uses.17,18 Another potential 
approach to deliver the gene of interest into wounds is the trans-
plantation of in vitro transfected cells. Transplantations of virally 
transfected keratinocytes,19 nonvirally transfected fibroblasts,20 
and adipose-derived stromal cells21 are promising approaches for 
wound treatment. Although nonviral overexpression of hCAP-18/
LL-37 in implanted skin tissues has shown promising activity in 
vivo,22 direct nonviral techniques to deliver the transgene of inter-
est would be more adequate for clinical use.
In this study, we hypothesize that the in vivo electropora-
tion of a plasmid encoding hCAP-18/LL-37 would represent an 
efficient nonviral technique to overexpress LL-37 host defense 
peptide within wounds. In vivo DNA electroporation is one of 
the most powerful nonviral delivery methods promoting both 
permeabilization of cell membranes and electrophoresis of the 
injected DNA.23 The combination of these two effects resulted in 
an enhanced transgene expression. Optimization of DNA electro-
poration into the skin led to a 100-fold increase in luciferase that 
was transiently expressed.24,25 Electroporation of DNA encoding 
TGF-β,26 KGF-1,27 and HIF-1α28 has previously been demon-
strated to promote wound healing in leptin receptor-deficient db/
db-mice. The study aimed at evaluating whether skin-targeted 
electroporation of a plasmid encoding hCAP-18/LL-37 would 
promote wound healing in nondiabetic and diabetic mice. In 
addition, the effect of this treatment was studied in a hindlimb 
ischemia model.
RESULTS
Combination of high- and low-voltage pulses allowed 
the most efficient gene expression into wounds
First, in vivo DNA electroporation in wounds was optimized by 
using reporter gene constructs to localize and quantify expres-
sion. After intradermal injection of a total amount of 50 µg of a 
plasmid encoding luciferase into four sites around each wound, 
we compared various electroporation parameters, as previously 
utilized for wound healing studies.27,28 The combination of one 
100 µs short, 700 V/cm high-voltage pulse immediately fol-
lowed by one 400 ms long, 200 V/cm low-voltage pulse (HV+LV) 
induced a ~100-fold increase in luciferase expression in wounds 
2 days after electroporation as compared to the injection of the 
plasmid without electroporation (no EP) (P < 0.001, analysis 
of variance (ANOVA)). The application of ten 20 ms 400 V/cm 
low-voltage pulses with 125 µs pauses between each pulse (LV) 
resulted in a lower but significant increase (P < 0.01), while six 
100 µs short and 1,800 V/cm high-voltage pulses interspersed 
with 125 µs pauses were not able to significantly enhance lucif-
erase expression compared to the no EP control, when applied 
using a plate-electrode (Figure 1a). Compared to LV or HV 
pulses alone, only the combination of HV+LV pulses displayed a 
significant increase in luciferase expression (approximately ten-
fold) on day 6 after electroporation (P < 0.05, ANOVA) (Figure 
1a). The influence of the plasmid dose on luciferase expression 
was studied and 50 µg was found to be the optimal dose of plas-
mid (P < 0.001, ANOVA). A higher dose of DNA did not lead to a 
higher luciferase expression (Figure 1b). Examining the kinetics 
of luciferase production, the application of the HV+LV treatment 
led to significantly enhanced protein expression that peaked at 
Figure 1 Optimization of DNA electroporation of cutaneous wounds. 
(a–c) In vivo luciferase imaging after DNA delivery. (a) Comparison of 
luciferase expression 2 and 6 days after intradermal injection of 50 µg 
of plasmid followed by (i) no electroporation (no EP), (ii) six 1,800 V/cm 
100 µs high-voltage pulses with 125 µs pause (HV), (iii) ten 400 V/cm 
20 ms low-voltage pulses with 125 µs pause (LV), and (iv) one 700 V/cm 
100 µs and 200 V/cm 400 ms electric pulses (HV+LV). (b) Influence of the 
plasmid dose on luciferase expression after no EP or HV+LV. (c) Kinetics 
of luciferase expression over 12 days after no EP or HV+LV. Graphs repre-
sent the mean values (±SEM), n = 5. Statistical analysis: one-way ANOVA 
and Tukey post-test (n.s., not significant; *P < 0.05, **P < 0.01, ***P < 
0.001). (d,e) Detection of GFP transcript. Five-micrometer thick cryo-
sections of intact wound edges 2 days after injection of 50 µg of pGFP 
followed by (d) no EP or (e) HV+LV. Bar = 30 µm.
105
Day 2
10 µg 50 µg 100 µg
**
***
***
**
** **
*
***
n.s
*
*
Li
gh
t e
m
iss
io
n 
(p/
s)
Day 6
No EP
No EP
HV
LV
HV + LV
HV + LV
No EP
No EP
HV + LV
HV + LV
106
107
108
109a
b
c
d e
105
Li
gh
t e
m
iss
io
n 
(p/
s)
106
107
108
109
105
0 2 4 6
Day after delivery
8 10 12
Li
gh
t e
m
iss
io
n 
(p/
s)
106
107
108
109
Molecular Therapy vol. 22 no. 4 apr. 2014 735
© The American Society of Gene & Cell Therapy
phCAP-18/LL-37 Electroporation for Wound Healing
day 2, stayed significantly high over 6 days, and appeared to be 
elevated for at least 12 days (Figure 1c). Enhanced gene delivery 
by HV+LV DNA electroporation was confirmed by fluorescence 
microscopy using a green fluorescent protein (GFP) reporter 
plasmid (pGFP). Gene expression after intradermal injection of 
naked DNA plasmids was mainly located in the dermis of the 
skin without expression in the epidermis (Figure 1d). In contrast, 
electroporation using HV+LV electric pulses (Figure 1e) resulted 
in stronger gene expression that appeared predominantly in kera-
tinocytes of the epidermis.
Electroporation of phCAP-18/LL-37 promoted wound 
healing in nondiabetic mice
Electroporation of plasmid pQE-hCAP-18/LL-37 (phCAP-18/
LL-37) that encodes the propeptide hCAP-18 led to the expression 
of LL-37 peptide by keratinocytes at the intact wound edges. This 
Figure 2 Electroporation of phCAP-18/LL-37 in wounds of C57BL/6 and db/db mice. (a,b) Detection of LL-37 transcript. 5 µm thick cryo-
sections of intact wound edges 2 days after injection of 50 µg of phCAP-18/LL-37 followed by HV+LV. Immunohistochemistry using (a) anti-IgG 
control or (b) anti-LL-37. Bar = 30 µm. Follow-up of wound healing on splint model in (c,f) nondiabetic and (d,g) diabetic mice. Graphs represent 
the mean values (±SEM), n = 5 for C57BL/6 and n = 6 for db/db mice. Statistical analysis: two-way ANOVA and Bonferroni post-test (*P < 0.05, 
**P < 0.01, ***P < 0.001). (e) RT-PCR analysis of VEGFa mRNA expression 12 days after electroporation of diabetic mice with pGFP or phCAP-18/
LL-37. Graph represents the mean values (±SEM) normalized to 18S rRNA, n = 6. Statistical analysis: t-test (*P < 0.05). (h,i) Follow-up of wound 
healing on wound histology stained with hematoxylin and eosin. Arrows indicate wounded panniculus carnosus by 4 mm punch biopsy, and bars 
demonstrate the wound edges of db/db mice 12 days after electroporation of (h) phCAP-18/LL-37 or (i) pGFP.
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cutaneous overexpression was demonstrated after immunostain-
ing with anti-LL-37 antibodies (Figure 2a,b). Electroporation of 
phCAP-18/LL-37 led to significantly earlier wound closure begin-
ning on day 5 with 35 ± 9% closure versus 23 ± 4% for the GFP con-
trol wounds (P < 0.05, ANOVA). Wound healing was significantly 
improved from day 8 to day 12, showing on average 54 ± 7% and 
77 ± 6% wound closure for LL-37 treatment versus 40 ± 7% and 
63 ± 6% for GFP control wounds, (P < 0.01, ANOVA) (Figure 2c,f).
Electroporation of phCAP-18/LL-37 restored delayed 
diabetic wound healing
Electroporation of phCAP-18/LL-37 was further analyzed in leptin-
receptor knock-out db/db mice, as a diabetic model for delayed 
wound healing. Blood glucose level measurements displayed an 
average of 272 ± 54 g/dl (mean ± SEM), confirming diabetes. Skin-
targeted electroporation of phCAP-18/LL-37 promoted the reepi-
thelialization of diabetic wounds. Digital analysis of the wound size 
demonstrated improved wound closure, evidenced from day 5 after 
electroporation for phCAP-18/LL-37 with 23 ± 7% versus 9 ± 8% 
for pGFP controls (P < 0.01, ANOVA). On day 8, wound sizes 
were reduced by 43 ± 5% versus 23 ± 11% for controls (P < 0.001, 
ANOVA). Finally, wound closure of LL-37 treated animals revealed 
61 ± 8% versus 43 ± 9% in the control group (P < 0.001, ANOVA) 
(Figure 2d,g). Subsequent histological analysis confirmed more 
efficient wound healing in LL-37 treated diabetic wounds (Figure 
2h,i). Electroporation of phCAP-18/LL-37 led to advanced approxi-
mation of the wound edges and the treated wounds were at a later 
state of reepithelialization, while pGFP control wounds displayed a 
larger distance between the wound borders. Reverse transcription 
polymerase chain reaction (RT-PCR) analysis demonstrated a sig-
nificant induction of VEGFa in wounds (P < 0.05, t-test), 12 days 
after electotroporation of phCAP-18/LL-37 (Figure 2e).
Electroporation of phCAP-18/LL-37 upregulated IL-6 
and the effect of hCAP-18/LL-37 was IL-6 dependent
RT-PCR analysis of acute nondiabetic and diabetic wounds 12 days 
after wounding revealed significant induction of IL-6 transcrip-
tion in both nondiabetic and diabetic wounds after phCAP-18/
LL-37 electroporation (P < 0.01, P < 0.05, t-test), (Figure 3a). To 
investigate the role of IL-6 on wounds treated by phCAP-18/LL-37, 
we performed in vitro wound migration assays with or without the 
addition of IL-6 blocking antibodies to LL-37–stimulated human 
HaCaT cells. A concentration of 0.5 µg/ml of LL-37 was able to 
stimulate cell migration (P < 0.05, t-test), (Figure 3b). Interestingly, 
LL-37 peptide-induced cell migration was reduced in the presence 
of anti-IL-6 antibody (Figure 3b,c). To determine the effect of LL-37 
peptide with or without addition of the IL-6 blocking antibody on 
the proliferation of human HaCaT cells, a colorimetric cell prolifer-
ation BrdU (5-bromo-2′-deoxyuridine)-ELISA was used. No influ-
ence of either LL-37 or the addition of the IL-6 blocking antibody on 
the proliferation rate of human HaCaT cells was observed (Figure 
3d). To confirm in vivo the role of IL-6 in the wound healing activity 
of phCAP-18/LL-37, wounds of nondiabetic mice depleted in IL-6 
were treated by electroporation of either phCAP-18/LL-37 or pGFP 
control while mice. The anti-IL-6 treatment completely suppressed 
the wound healing activity of phCAP-18/LL-37 which became sim-
ilar to pGFP control (Figure 3e).
Angiogenesis and reperfusion after induction of 
hindlimb ischemia were enhanced by intradermal 
electroporation of phCAP-18/LL-37
Next, we determined the effect of skin-targeted electroporation 
of phCAP-18/LL-37 in a previously described ischemic hindlimb 
model in mice,29–31 using laser doppler imaging which allows quan-
tification of perfusion. In order to treat the entire ischemic area, 
we doubled the dose of plasmid and we intradermally injected 
two sites each with 50 µg. Intradermal electroporation of phCAP-
18/LL-37 enhanced blood perfusion in the ischemic hindlimb, 
suggesting an accelerated sprouting of new and more functional 
blood vessels29 (Figure 4a,b). One week after surgery and cuta-
neous in vivo electroporation of phCAP-18/LL-37, more than 
75 ± 11% reperfusion was achieved compared to 45 ± 11% with 
the pGFP control treatment (P < 0.001 ANOVA). pGFP-treated 
ischemic limbs still showed diminished perfusion, whereas elec-
troporation of phCAP-18/LL-37 led to significant reperfusion of 
the ischemic gap between the proximal and distal resection points 
of the femoral vessels. The blood flow was increased by a factor 
of two and a 85 ± 7% recovery was obtained with intradermal 
electroporation of phCAP-18/LL-37 into the skin at day 12 after 
surgery, whereas the perfusion in the pGFP controls remained 
significantly reduced (P < 0.001 ANOVA).
Intradermal electroporation of phCAP-18/LL-37 
protected against muscular atrophy in ischemic 
hindlimb
Mice were sacrificed 12 days after surgery and treatment in order 
to assess the muscular atrophy induced by hindlimb ischemia. 
The percentage of muscle atrophy, calculated by comparing isch-
emic gastrocnemius to the respective contralateral muscle, was 
12 ± 5% for control mice treated by electroporation of pGFP and 
was significantly reduced to 4 ± 8% after phCAP-18/LL-37 electro-
poration (Figure 4f). Histology of the muscle fibers confirmed the 
protective effect of phCAP-18/LL-37 treatment against muscular 
atrophy (Figure 4c–e), in agreement with the drastic increase of 
phCAP-18/LL-37 induced blood perfusion.
Skin-targeted in vivo electroporation of phCAP-18/
LL-37 stimulated the transcription of angiogenic 
cytokines and receptors in ischemic hindlimb muscles
Gastrocnemius muscle samples demonstrated a significant 2.5 
to 3-fold induction of the transcription of angiogenic cytokines 
VEGFa and SDF-1a (P < 0.05, t-test), 12 days after the induction 
of ischemia and cutaneous electotroporation of phCAP-18/LL-37 
(Figure 4g,h). These elevated cytokines were associated with a sig-
nificant increase in the transcription of their receptors VEGFR-1 
and CXCR-4 (P < 0.05, t-test) (Figure 4i,j). It has been suggested 
that quantitation of receptors for angiogenic cytokines by RT-PCR 
could reflect the presence of mobilized circulating angiogenic cells 
which characteristically express these receptors.32,33
DISCUSSION
We have previously described that transient cutaneous adeno-
viral delivery of hCAP-18/LL-37 combat wound infection in an 
infected rat burn model showed superiority to topical peptide 
treatment.15 As our subsequent attempts at topical LL-37 peptide 
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treatment failed to promote consistent wound healing in murine 
models,12 we hypothesized that skin-targeted electroporation of a 
plasmid encoding this host defense peptide would promote the 
healing of nondiabetic and diabetic wounds. We demonstrated 
here that the noninvasive electroporation of the wound edges 
was a convenient nonviral alternative for the direct treatment of 
wounds using a plasmid encoding hCAP-18 to overexpress LL-37.
First, we showed that gene expression in the wound area was 
higher and lasted significantly longer after electroporation with 
combined HV+LV pulses as compared to previously reported 
protocols involving administration of a series of pulses with the 
same field strength27,28 (Figure 1a). In agreement with previous 
reports,34,35 gene expression after intradermal injection of naked 
pGFP was mainly located in the dermis of the skin without expres-
sion in the epidermis (Figure 2a) whereas electroporation of 
pGFP induced strong expression predominantly in keratinocytes 
of the epidermis (Figure 2b). As keratinocytes adjacent to the 
wound bed are at the origin of reepithelialization,36 we targeted 
the wound edges for promoting healing. Muscle contractions at 
the time of pulse application and local pain are reported adverse 
effects of electroporation.37 Therefore, electrodes were designed 
to reduce potential pain during the application of a current.38,39 
Another approach to further reduce potential pain is to reduce the 
number of pulses: the use of high- and low-voltage pulse combi-
nations have been discussed intensively, with the conclusion that 
the administration in two different steps provides permeabiliza-
tion and electrophoresis to drive the DNA plasmid into the target 
cells in vivo.40,41 By targeting the skin, this combination of pulses 
has been shown to significantly increase gene expression.24,25,40 
Using this optimized delivery method, we transfected the epi-
dermal keratinocytes of the intact wound edges with phCAP-18/
LL-37 as demonstrated by LL-37 immunohistochemistry (Figure 
2b). Moreover, skin electroporation of phCAP-18/LL-37 was 
able to significantly improve wound closure in both nondiabetic 
Figure 3 Role of IL-6 on keratinocyte migration and wound healing. (a) RT-PCR analysis of IL-6 mRNA expression after DNA electroporation of 
pGFP or phCAP-18/LL-37, normalized to 18S rRNA. Graph represents the mean values (±SEM), n = 5 for nondiabetic and n = 6 for diabetic mice. 
Statistical analysis: t-test (*P < 0.05, **P < 0.01). (b,c) In vitro wound migration and (d) BrdU proliferation assay. White dotted lines display the 
cell free area at day 0 after removal of silicone inserts. Human HaCaT cells were incubated for 24 hours in (i) 200 µg/ml anti-rabbit IgG as control, 
(ii) 0.5 µg/ml LL-37 peptide and 200 µg/ml anti-rabbit IgG, (iii) 0.5 µg/ml LL-37 peptide and 200 µg/ml anti-IL-6 or (iv) 200 µg/ml anti-IL-6. Graphs 
represent the mean values (±SEM), n = 3. Statistical analysis: one-way ANOVA and Tukey post-test (*P < 0.05). (e) Wound healing activity after DNA 
electroporation in C57BL/6 mice treated (n = 7) or not (n = 5) with anti-IL-6 mAb. Graph represents the mean value (±SEM) of the difference observed 
between phCAP-18/LL-37 and pGFP treatments. Statistical analysis: two-way ANOVA (P value: 0.0002).
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(Figure 2c,f) and diabetic mice models (Figure 2d,g), confirming 
the hypothesis that skin-targeted electroporation induces an effi-
cient nonviral delivery of host defense peptide in wounds.
Further, our study provided additional insights into an 
understanding of LL-37 induced wound healing by demonstrat-
ing the essential involvement of IL-6, a pleiotropic cytokine that 
can influence growth and differentiation of various cells types. 
It has been previously demonstrated that IL-6-deficient mice 
display a dramatic delay in wound healing.42 Epidermal kerati-
nocytes have been identified as the main source of IL-6 produc-
tion in the skin43 and several host defense peptides including 
LL-37 have been shown to stimulate IL-6 expression.44 Here, 
we observed a significant increase in IL-6 transcription after 
electroporation of phCAP-18/LL-37 (Figure 3a). To shed light 
onto the influence of IL-6 for wound repair after overexpres-
sion of LL-37, we performed in vitro wound migration assays 
using human HaCaT cells. LL-37 stimulated cell migration 
without directly affecting cell proliferation, supporting previ-
ous results obtained using adenovirus-transfected HaCaT cells 
overexpressing LL-37.45 Consistent with a major role for IL-6, 
the LL-37 peptide-induced cell migration was abolished in 
the presence of an IL-6 blocking antibody (Figure 3b,c). We 
also demonstrated that the wound healing activity promoted 
by electroporation of phCAP-18/LL-37 was suppressed when 
mice were concomitantly treated by IL-6 neutralizing antibody 
(Figure 3e). These in vitro and in vivo data thus strongly suggest 
that LL-37 promoted wound healing by inducing IL-6 depen-
dent keratinocyte migration.
Figure 4 Blood perfusion, molecular atrophy, and expression of angiogenic cytokines and receptors after electroporation of phCAP-18/LL-37 
in ischemic hindlimb model. (a,b) Follow-up of perfusion by laser Doppler imaging. Skin-targeted electroporation was performed at day 0 after 
surgery. Black arrows demonstrate the proximal and white arrows show the distal resection height of the femoral vessels. Graphs represent the mean 
values (±SEM), n = 6. Statistical analysis: two-way ANOVA and Bonferroni post-test (n.s., not significant; ***P < 0.001). Hematoxylin and eosin stained 
transverse muscle sections 12 days after cutaneous electroporation using (c) pGFP or (d) phCAP-18/LL-37 as compared to (e) healthy gastrocnemius 
muscle. (f) Muscle weight loss at day 12 after induction of ischemia and treatment. Graph represents the mean values (±SEM), n = 6. Statistical analy-
sis: t-test (*P < 0.05). RT-PCR analysis of (g) VEGFa, (h) VEGF-R, (i) SDF-1a, and (j) CXCR-4 mRNA expression 12 days after electroporation of pGFP 
or phCAP-18/LL-37. Graphs represent the mean values (±SEM) normalized to 18S rRNA, n = 6. Statistical analysis: t-test (*P < 0.05).
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In the past, cutaneous electroporation of FGF-2 has promoted 
increased perfusion and angiogenesis in a hindlimb ischemia 
model.46 Here, we propose that electroporation of phCAP-18/
LL-37 into the skin after induction of hindlimb ischemia pro-
moted neovascularization and the induction of pro-angiogenic 
cytokine expression in the muscle (Figure 4). The involvement of 
VEGF in LL-37 activity was initially denied as it was shown that 
the addition of anti-VEGF did not inhibit LL-37 induced prolif-
eration of endothelial cells in vitro.47 However, it has been shown 
later that LL-37 was able to regulate the overexpression of VEGF 
in keratinocytes.48 In our study, we provide further evidence that 
LL-37 indeed has an influence on the expression of angiogenic 
cytokine, as VEGFa is significantly upregulated after electropora-
tion of phCAP-18/LL-37 (Figure 2e, 4g). It suggests that LL-37 
induced VEGF expression after skin-targeted electroporation may 
contribute to the angiogenic effect of LL-37 in vivo. In addition, 
we observed reduced muscle atrophy when the ischemic limbs 
were treated by phCAP-18/LL-37 electroporation (Figure 4f).
The skin is an attractive target for drug delivery and local 
gene therapy, both in regard of its accessibility and behavior as 
immunocompetent organ. By delivering plasmid to wounds using 
electroporation, we have shown promising results that pave the 
way for potential clinical applications. As skin-targeted electro-
poration of LL-37 reduces ischemic injury its application in the 
clinical setting could help reducing surgical flap loss. Patients with 
peripheral artery disease could benefit from the revascularization 
potency of this new treatment. As LL-37 has displayed antimicro-
bial activity in preclinical studies, electroporation of LL-37 could 
greatly contribute to the treatment of wound infection and help 
restoring the underexpression of LL-37 in diabetic wounds.11 
Whereas our previous attempt of topical application of LL-37 
failed to improve diabetic delayed wound healing,12 local transient 
gene therapy using a plasmid encoding hCAP-18/LL-37 restored 
the healing of diabetic wounds.
In conclusion, we introduced a novel nonviral gene therapeu-
tic technique to treat nondiabetic and wounds and to promote 
angiogenesis with LL-37. Moreover, we uncovered an IL-6 depen-
dency for LL-37 induced wound healing in vitro and in vivo. More 
studies will be needed to further evaluate the clinical applicability 
of in vivo phCAP-18/LL-37 electroporation.
MATERIALS AND METHODS
Plasmids. Luciferase and green fluorescent protein genes originate from 
the pcDNA3.1-Luc (Invitrogen, Darmstadt, Germany) and the pEGFP-N1 
(Clontech, Palo Alto, CA), respectively. The gene encoding human hCAP-
18/LL-37 peptide originates from Ad5-hCAP-18 virus,15 which was kindly 
provided by The Vector Core (Gene Therapy Program, Division of Medical 
Genetics, Department of Medicine, University of Pennsylvania). DNA 
cloning was performed using pQE-TriSystem plasmid vector (Qiagen, 
Hilden, Germany) according to the manufacturer’s protocol. Briefly, the 
individual PCR products were gel purified and digested with BamHI and 
Notl (Luciferase), EcoRI and HindIII (GFP), and BamHI and HindIII 
(hCAP-18/LL-37). Inserts were then ligated with the pQE-TriSystem 
expression vector by T4 DNA ligase, transformed into E. coli XL-1-blue 
and selected on ampicillin containing LB agar plates. Plasmid purifications 
were carried out with endotoxin-free plasmid gigaprep (Qiagen) accord-
ing to manufacturer’s protocol and dissolved in sterile phosphate-buffered 
saline (PBS). The correct identity of each construct was confirmed by 
sequencing (GENterprise Genomics, Mainz, Germany).
Animals. Seven-week-old C57BL/6 mice (Janvier, Le Genest St Isle, 
France) were used for the luciferase protein expression assay and for the 
nondiabetic wound healing study. For the study of diabetic wound heal-
ing, 7-week-old leptin-receptor deficient db/db mice (Charles River, 
L’Arbresle, France) were used. Animals were anaesthetized using a mixture 
of ketamine (Anesketin, Eurovet, Heusden-Zolder, Belgium) and xylazine 
(Sigma, Bornem, Belgium) or by isoflurane inhalation. All experimental 
protocols with mice were approved by the Ethical Committee for Animal 
Care and Use of the Faculty of Medicine of the Université catholique de 
Louvain, Brussels, Belgium.
Electroporation of wounded skin. The dorsal surface was shaved 1 day prior 
to the experiments with depilatory cream (Veet for sensitive skin, Belgium), 
in order to thoroughly remove all hair. At the day of wounding, the dorsum 
of each anesthetized animal was disinfected with polyvidone iode. Two to 
four full-thickness wounds, one to two on each side of the midline, were 
created using a 4 mm punch biopsy. Plasmids diluted in sterile PBS to a total 
volume of 80 µl were intradermally injected in four quadrants around each 
wound. Each wound and the surrounded skin were then caught in between 
a 10 mm width and 2 mm spaced plate-electrode, and the electroporation 
was performed by a Cliniporator system (IGEA, Carpi, Italy). Three types 
of pulses were applied: (i) one 700 V/cm 100 µs and one 200 V/cm 400 ms 
electric pulses, without pause in between (HV+LV24,25), (ii) ten 400 V/cm 
20 ms low-voltage pulses with 125 µs pauses between each pulse (LV28), or 
(iii) six 1,800 V/cm 100 µs high-voltage pulses with 125 µs pauses (HV27). 
For all experiments, conductive gel was applied to ensure electrical contact 
with the skin (EKO-GEL, ultrasound transmission gel, Egna, Italy).
In vivo luciferase-Imaging. Injection of a single dose of luciferin (150 mg/
kg, ip, Promega, Leiden, Netherlands) at different time points after electro-
poration of pQE-Luciferase allowed in vivo detection of bioluminescence 
on an IVIS50 imaging system (Xenogen, Hopkinton, MA), as previously 
described.49
Immunostaining. Biopsy specimens were taken 2 days after electropora-
tion of pGFP and phCAP-18/LL-37, frozen in liquid nitrogen-cooled 
isopentane and cut into five micrometer-thick cryosections. Sections 
of pGFP-treated wounds were rinsed with PBS and counterstained with 
the nuclear stain DAPI. Sections of hCAP-18/LL-37 wounds were immu-
nostained with goat anti-rabbit-LL-37 antibody, kindly provided by Prof. 
Gallo (Division of Dermatology, Department of Medicine, University 
of California, San Diego, CA). The slides were incubated overnight with 
anti-LL-37 at 4 °C, then rinsed with PBS and incubated with biotinylated 
anti-goat antibody at room temperature. After the washing procedure, sec-
tions were incubated in streptavidin Alexa Fluor488. The slides were rinsed 
again and DAPI counterstaining was performed. Finally, the slides were 
covered with fluorescent mounting medium (Dako, Hamburg, Germany) 
and images were taken by using an Axioskop 2 plus microscope (Zeiss, 
Jena, Germany) connected to an AxioCam HRC camera (Zeiss).
Splint model for wound healing. To guaranty better reproducibility of 
the results by reducing wound contraction, wounds were fixed with a 
silicone splint. Donut-shaped splints with an outer diameter of 12 mm 
and an inner diameter of 6 mm were cut from a 0.5-mm thick silicone 
sheet (Grace Bio-Laboratories, Bend, OR). An immediate-bonding 
adhesive (Hollister, Libertyville, IL) was applied to fix the splint cen-
trally to the wound, followed by 4-0 interrupted nylon sutures (Ethicon, 
Somerville, NJ). Wounds were covered by Jelonet paraffin gauze (Smith 
& Nephew, Hamburg, Germany) and Tegaderm as a transparent occlu-
sive wound dressing (Tegaderm, 3M, Neuss, Germany), and changed 
every 2–3 days. The wound areas were digitally captured on days 0, 2, 5, 
8, and 12 using a Leica IC80 HD stereo microscope with Leica LAS EZ 
V 1.8.0 Software (Leica, Heerbrugg, Switzerland). The wound size was 
evaluated using ImageJ 1.45s Software (National Institutes of Health, 
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Bethesda, MD) and calculated as the ratio of the wound borders to the 
inner 6 mm silicone ring. Results are expressed as the percentage of 
wound coverage compared to day 0 after surgery. To investigate the role 
of IL-6 in the healing process, nondiabetic mice received a daily intra-
peritoneal injection of 250 µg (in 250 µl PBS) of neutralizing anti-mouse 
IL-6 mAb (BioXcell, West Lebanon, NH), for 7 days, starting the day of 
surgery and electroporation. This protocol was previously described to 
deplete mice in IL-6.50
Quantitative real-time RT-PCR analysis of wound samples. Mice were 
sacrificed 12 days after treatment and the wound samples were taken and 
weighed to ensure that they did not to exceed 50 mg. Tissues were stored 
at −80 °C in RNAlater until further processing. Isolation of total RNA 
was done using Trizol, following the manufacturer’s instructions for isola-
tion of total RNA. RNA was eluted in a final volume of 30 μl RNase-free 
water. The concentration of RNA was determined using the Eppendorf 
Biophotometer (Eppendorf, Hamburg, Germany). One microgram of 
total RNA was transcribed into cDNA using the SuperScript II First Strand 
Synthesis System for RT-PCR (Invitrogen, Karlsruhe, Germany), follow-
ing the manufacturer’s instructions and using random hexamer primers. 
Relative quantification of mRNA was performed using the SYBR Green I 
fluorescent dye (Light Cycler FastStart DNA Master SYBR Green I, Roche 
Applied Science, Mannheim, Germany) and a Light Cycler 1.0 (Roche). 
The PCR reactions were performed with 2 μl of cDNA, 0.5 μmol/l of sense 
and antisense primers, 3 mmol/l MgCl2 and 2 μl of FastStart SYBR Green 
reaction mix in a total volume of 20 μl. The cycling conditions were as fol-
lows: 95 °C for 10 minutes at a ramp speed of 20 °C/second, 50 cycles con-
sisting of 94 ° C for 15 seconds at a ramp speed of 20 °C/second, a primer 
specific annealing temperature for 10 seconds at a ramp speed of 20 °C/
second, 72 °C for 10 seconds at a ramp speed of 20 °C/second, followed 
by a melting point analysis: 95 °C for 0 second at a ramp speed of 20 °C/
second, 65 °C for 15 seconds at a ramp speed of 20 °C/second, 95 °C for 0 
second at a ramp speed of 0.1 °C/second, and finally a cooling phase: 40 
°C for 30 seconds at a ramp speed of 20 °C/second. All primer pairs were 
validated to generate a single PCR product and mRNA concentrations 
were normalized to 18S rRNA in each sample and expressed as relative 
expression compared to controls. Primer sequences are as follows: 18S 
sense 5′–gaaactgcgaatggctcattaaa-3′ and 18S antisense 5′-cacagttatccaag-
taggagagg-3′; VEGFa33 sense 5′-cttgttcagagcggagaaagc-3′, and antisense 
5′-acatctgcaagtacgttcgtt-3′; IL-6 sense 5′-ccggagaggagacttcacag-3′ and 
antisense 5′-tccacgatttcccagagaac-3′.
Histology analysis of full-thickness wounds. Wound samples from each 
experiment were fixed in 4% buffered paraformaldehyde. Tissue samples 
were stained with hematoxylin/eosin and images taken with an AxioCam 
camera on an Axioplan microscope (Carl Zeiss GmbH, Oberkochen, 
Germany).
In vitro wound migration assay. HaCaT is a human epidermal keratino-
cyte-derived immortalized cell line. HaCaT cells (kindly supplied by Prof. 
Fusenig, University of Heidelberg, Germany), were cultured in Dulbecco’s 
modified Eagle medium with 10% fetal bovine serum and 1% penicil-
lin/streptomycin at 37 °C in humidified atmosphere at 5% CO2. Culture 
medium was changed every second day. LL-37 was synthesized by The 
Nucleic Acid/Protein Synthesis Unit at University of British Columbia 
using solid phase FMOC-chemistry and purified to a purity >95% using 
reversed phase high-performance liquid chromatography. Peptide mass 
and lack of contaminating peptides were confirmed by mass spectrometry. 
HaCaT cells were seeded into 12-well plates, in each of the two compart-
ments of Ibidi silicone chamber (12,500 cells in 80 µl/compartment) (Ibidi 
GmbH, Munich, Germany). After 24 hours the silicone chambers were 
carefully removed, cells were rinsed with PBS, and 1 ml culture medium 
was added, containing either anti-rabbit-IgG (200 µg/ml) as a control, 
anti-rabbit-IgG + LL-37 (0.5 µg/ml), anti-IL-6 (200 µg/ml) (Rockland, 
Gilbertsville, PA) or anti-IL-6 + LL-37 (0.5 µg/ml). Each experiment was 
performed in triplicate. Images were taken with an AxioCam camera on 
an Axioplan microscope (Carl Zeiss GmbH) directly after the addition of 
the indicated medium and 24 hours after their incubation. The wound size 
was evaluated using ImageJ 1.45s Software (National Institutes of Health) 
and the results are expressed in percent as ratio of the cell free area after 24 
hours of incubation compared to the area before incubation.
BrdU proliferation assay. A colorimetric cell proliferation assay involving 
incorporation of BrdU (5-bromo-2′-deoxyuridine)-ELISA (Roche) was 
performed according to the manufacturer’s protocol. HaCaTs were seeded 
in a 96-well microtiterplate (Omnilab, Bremen, Germany). After 24 hours, 
either anti-rabbit-IgG (200 µg/ml) as control, anti-rabbit-IgG + LL-37 
(0.5 µg/ml), anti-IL-6 (200 µg/ml), or anti-IL-6 + LL-37 (0.5 µg/ml) were 
added. Each experiment was performed in triplicates. After additional 
incubation of 24 hours, anti-BrdU conjugated to peroxidase was added. 
Based on the incorporation of the thymidine analogue BrdU during DNA-
synthesis, proliferation of HaCaT cells was indirectly quantified by using 
a microplate absorbance reader Sunrise (Tecan trading AG, Männedorf, 
Switzerland). KC4 software (BioTek 34 Instruments, Bad Friedrichshall, 
Germany) was used for the analysis.
Ischemic hindlimb model. The femoral artery and vein ligation and resec-
tion model was used as described previously.29–31 The mice were anaesthe-
tized as described above and both hindlimbs were shaved. After incision 
of the skin at the lateral thigh, mice underwent unilateral 10-mm–length 
resection of the proximal femoral artery and vein under a stereoscopic 
microscope. The femoral nerve was carefully preserved during the micro-
surgical procedure. After skin closure, 100 µg of phCAP-18/LL-37 or 
pGFP to a total volume of 80 µl PBS were intradermally injected above 
the resection area. The entire limb was then placed between a 10 mm 
width and 4 mm spaced plate-electrode and the electroporation was 
performed using a Cliniporator system (IGEA, Carpi, Italy) with a com-
bination of one high-voltage (700 V/cm, 100 µs) and one low-voltage 
(200 V/cm, 400 ms) electric pulse. On the indicated days, anesthetized 
mice were placed on a heating pad (37 °C), and the perfusion of both 
the wounded and the contralateral healthy hindlimb was measured using 
a Laser Doppler Flowmeter (Moor Instruments, Axminster, UK). Blood 
perfusion of the ischemic area was quantified on the basis of colored pixel 
histograms and normalized to the perfusion of the healthy contralateral 
leg of the same animal. Results are expressed as percentage of reperfusion 
compared to day 0 after surgery.
Determination of muscular atrophy. Mice were sacrificed 12 days after 
femoral artery and vein dissection. For the assessment of skeletal muscle 
atrophy gastrocnemius muscles from the ischemic and healthy hindlimb 
were carefully microdissected from adjacent tissue and weighted. Muscle 
weight loss was calculated as weight ratio between the ischemic and the 
contralateral healthy muscle of each animal. For histological analysis tis-
sue samples were sectioned perpendicularly to the main axis, and fixed in 
4% buffered paraformaldehyde. Cross sections were stained with hema-
toxylin/eosin and images taken with an AxioCam camera on an Axioplan 
microscope (Carl Zeiss GmbH).
RT-PCR analysis of the muscle tissue of ischemic hindlimbs. Gastrocnemius 
muscles were sampled and processed as described above. Primer sequences 
for angiogenic cytokines and their receptors are as follows:33 VEGFa sense 
5′-cttgttcagagcggagaaagc-3′, and antisense 5′-acatctgcaagtacgttcgtt-3′; 
SDF-1a sense 5′-gagagccacatcgccagag-3′, and antisense 5′-tttcgggtcaat-
gcacacttg-3′; VEGFR-1 sense 5′-tggacccagatgaagttccc-3′, and antisense 
5′-gcgatttgcctagtttcagtct -3′; CXCR-4 sense 5′-agcatgacggacaagtacc-3′, and 
antisense 5′-gatgatatggacagccttacac-3′.
Statistical analysis. Results are presented as means ± SEM. Differences in 
means between groups were analyzed for significance using Student’s t-test 
or ANOVA as appropriate (GraphPad Prism Software, San Diego, CA).
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